4
Clinical Trials associated with BC-006A phase 1, randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of a subcutaneous injection of BC-006 in adults with obesity- part 2
Start Date28 Jul 2025 |
Sponsor / Collaborator- |
A phase 1, randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of a subcutaneous injection of BC-006 in adults with obesity- part 1
Start Date27 Mar 2025 |
Sponsor / Collaborator- |
An Exploratory Clinical Study to Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BC006 Monoclonal Antibody Injection in Patients With Advanced Solid Tumors Including Giant Cell Tumor of Tendon Sheath
This is a first in human, open-label, exploratory phase I clinical study including dose escalation (Ia) and dose expansion (Ib) stage. It aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BC006 in giant cell tumor of tendon sheath (GCTTS) and other advanced solid tumors.
100 Clinical Results associated with BC-006
100 Translational Medicine associated with BC-006
100 Patents (Medical) associated with BC-006
100 Deals associated with BC-006